Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able to read consent form and give informed consent.~* At least 15 years old.~* Histologically confirmed non-lymphoid hematological malignancy.~* Recipient of T cell depleted bone marrow (BM) or peripheral blood stem cell (PBSC) transplant from a 6/6 HLA (A, B, DR by intermediate resolution) identical related or unrelated donor after myeloablative conditioning.~* Received TCD HCT containing \< 1x105 CD3+ T cells/kg of recipient.~* Patient included in at least one of the following categories:~  * AML in 2nd or greater complete remission.~ * High-risk AML (high-risk cytogenetics, undifferentiated leukemia, secondary AML, antecedent MDS) in 1st remission.~ * CML in 2nd or greater chronic phase, 2nd or greater accelerated phase.~ * MDS intermediate or high risk by IPSS criteria.~* History of opportunistic infection (CMV viremia requiring anti-viral therapy, PCP pneumonia, mycobacterial infection, herpes zoster, viral respiratory infection (influenza, RSV, para-influenza), etc.~* CD4+ T cell count \< 100 at 6 months post-transplant.~* At high risk for opportunistic infection (e.g., history of treated invasive fungal infection prior to the transplantation, positive CMV serology in patient, or positive toxoplasmosis serology in donor and patient, etc.).~* 60 - 210 days post transplant.~* In remission at the time of initiation of CYT107.~* Documented engraftment with sustained neutrophil counts of at least 1000/mcl and untransfused platelet counts \> 20 000/mcl for 3 consecutive lab values (the last one tested \<10 days before initiation of treatment) on 3 different days prior to treatment. Patients who have engrafted but require G-CSF for myelosuppressive antibiotics or antiviral medications are eligible if they require G-CSF no more than twice weekly and their ANC remains \>1000/mcl.~* KPS \> 60%.~* Adequate organ function:~  * Cardiac: No evidence of change in cardiac function by history, exam and/or EKG post-HCT.~ * Pulmonary: Absence of dyspnea or hypoxia (\< 90% of saturation by pulse oxymetry on room air).~ * Hepatic: Bilirubin \<= 1.5 X ULN, AST (SGOT) and /or ALT (SGPT) \<= 2.5 X ULN. PT/PTT \< 1.5 X ULN.~ * Renal: Calculated Creatinine clearance \> 60 mL/min/1.73 m2. \[Note: all transplant patients had an ejection fraction of \> 40% on their pre-transplant echocardiogram and a DLCO \> 50% of predicted (corrected for hemoglobin)\]~Exclusion Criteria:~* No evidence or history of acute GVHD or of chronic GVHD.~* No recurrent leukemia post HCT.~* No active uncontrolled viral, bacterial or fungal infection.~* No documented HIV-1 or -2, HBV or HCV infection at any time before or after transplant (a positive hepatitis B serology indicative of a previous immunization is not an exclusion criteria).~* Not be receiving systemic corticosteroid, anti-mitotic agent or other immunosuppressive treatment.~* Not receiving Growth Hormone or gonadotropin agonists/ antagonists.~* Not receiving any cytokine support other than G-CSF post-HCT.~* Not receiving concurrent treatment with another investigational drug and/or biological agent.~* Not receiving anticoagulant therapy.~* No uncontrolled hypertension.~* No history of lymphoid malignancy (e.g. Hodgkin disease, non Hodgkin lymphoma, Acute Lymphoblastic Leukemia and Chronic Lymphocytic Leukemia) or acute biphenotypic leukemia.~* No peripheral lymphadenopathy (any lymph node \> 1 cm).~* No history of EBV associated lymphoproliferation.~* No EBV viremia equal to or greater than 500 copies EBV DNA/mL of blood by quantitative PCR.~* No history of autoimmune disease nor a HCT donor with a history of an autoimmune disease.~* Fertile patients must use effective birth control. Not pregnant or nursing. Negative pregnancy test within 2 weeks of study treatment.~* QTc prolongation (QTc \> 470 ms) or prior history of significant arrhythmia or ECG abnormalities.~* No active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.~* Any past or current psychiatric illness that, in the opinion of the investigator, would interfere with adherence to study requirements or the ability and willingness to give written informed consent.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- I (Type: EXPERIMENTAL): Single arm dose escalation study. Three successive cohorts of 3 patients each. Doses to be evaluated: 10, 20, and 30 mcg/kg/dose for 3 consecutive doses.~CYT107 is a recombinant protein belonging to the class of growth factors known as cytokines.~CYT107 is a heavily glycosylated and sialylated form of recombinant human Interleukin-7.~CYT107 is supplied as a sterile colorless liquid at a concentration of 4 mg/ml.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete